Diabetes and hypertension: Pivotal involvement of purinergic signaling

Autor: Vera Maria Morsch, Karine Paula Reichert, Milagros Fanny Vera Castro, Naiara Stefanello, Vanessa Valéria Miron, Andréia Machado Cardoso, Maria Rosa Chitolina Schetinger, Charles Elias Assmann, Nathieli B. Bottari
Jazyk: angličtina
Rok vydání: 2021
Předmět:
BP
blood pressure

HIF-1α
hypoxia-inducible factor-1α

Adenosine
Up4A
uridine adenosine tetraphosphate

Cell Communication
Review
APCs
antigen presenting cells

BFR
blood flow restriction

0302 clinical medicine
PNP
purine nucleoside phosphorylase

Diabetic cardiomyopathy
Purinergic P2 Receptor Antagonists
HIAE
high intensity aerobic

Medicine
NOS
nitric oxide synthase

5'-Nucleotidase
5′-NT
CD73
ecto-5′-nucleotidase

Ectonucleotidases
GLP-1
glucagon-like peptide-1

General Medicine
PAP
prostatic acid phosphatase

GLUT
glucose transporter

NTPDase1/CD39
E-NTPDase family

030220 oncology & carcinogenesis
TReg
regulatory T cells

ATP
adenosine 5′-triphosphate

P1
purinergic receptors family 1

DBP
diastolic blood pressure

RM1-950
ADP
adenosine 5′-diphosphate

STZ
streptozotocin

LIAE
low intensity aerobic exercise

HIIT
high-intensity intermittent training

03 medical and health sciences
Antigens
CD

Diabetes Mellitus
Humans
Exercise
Ado
Adenosine

PBMCs
peripheral blood mononuclear cells

Pharmacology
NO
nitric oxide

Receptors
Purinergic P2

UTP
uridine-5′-triphosphate

Receptors
Purinergic P1

T2DM
type 2 diabetes mellitus

medicine.disease
IL
interleukin

CGA
chlorogenic acid

030104 developmental biology
Glucose
ER
endoplasmatic reticulum

GABA
gamma-aminobutyric acid

Ino
inosine

PKA
protein kinase A

SHR
spontaneously hypertensive rat

0301 basic medicine
Adenosine Deaminase
STAT3
signal transducer and activator of transcription 3

SIT
sprint interval training

UDP
uridine diphosphate

Bioinformatics
Adenosine deaminase
VO2máx
maximal oxygen uptake

DM
diabetes mellitus

E-NPP
ecto-nucleotide pyrophosphatase/phosphodiesterase

Receptor
ADA
adenosine deaminase

NOD-mice
Non-obese diabetic mice

NF-κB
nuclear factor kappa B

TNF-α
tumor necrosis factor α

biology
AMP
adenosine 5′-monophosphate

Apyrase
T1DM
type 1 diabetes mellitus

Purinergic receptor
E-NTPDase
ecto-nucleoside triphosphate diphosphohydrolase

eNOS
endothelial nitric oxide synthase

MICT
moderate intensity continuous training

Purinergic signalling
IRS-1
insulin receptor substrate 1

VEGF
vascular endothelial growth factor

mRNA
messenger RNA

MSNA
muscle sympathetic nerve activity

Hypertension
Ap3A
diadenosine triphosphate

Blood pressure
Diet
Healthy

DCs
dendritic cells

Purinergic receptors
Signal Transduction
medicine.drug
P2Y
purinergic metabotropic receptor family 2

TNAP
tissue-nonspecific alkaline phosphatase

HbA1c
glycosylated hemoglobin

P2 receptor
CNS
central nervous system

APs
alkaline phosphatases

SIRT1
Sirtuin 1

GPCRs
G-protein-coupled receptors

L-NAME
L-NG-nitroarginine methyl ester

P2X
purinergic ionotropic receptor family 2

Diabetes mellitus
Animals
TXA2
thromboxane A2

ComputingMethodologies_COMPUTERGRAPHICS
NLRP3
NLR family pyrin domain containing 3

cAMP
cyclic adenosine 5′-monophosphate

business.industry
SBP
systolic blood pressure

AngII
angiotensin-II

ATP
AMPK
AMP-activated protein kinase

NFAT
nuclear factor of activated T-cells

Purinergic P1 Receptor Antagonists
DAMP
molecular pattern associated with damage

Purines
TGF-β1
transforming growth factor-beta 1

biology.protein
Therapeutics. Pharmacology
business
DAG
diacylglycerol
Zdroj: Biomedicine & Pharmacotherapy, Vol 137, Iss, Pp 111273-(2021)
Biomedicine & Pharmacotherapy
ISSN: 0753-3322
Popis: Graphical abstract
Highlights • The coexistence of diabetes and hypertension represents a major risk factor for the onset of cardiovascular problems. • The purinergic signaling pathway constitutes a ubiquitous system of cell–cell communication. • Purinergic system plays a pivotal role in physiopathological conditions. • Several alterations in purine metabolism have been demonstrated in diabetes and hypertension. • Purinergic system can be an important target related to therapeutic approaches in diabetes and hypertension.
Diabetes mellitus (DM) and hypertension are highly prevalent worldwide health problems and frequently associated with severe clinical complications, such as diabetic cardiomyopathy, nephropathy, retinopathy, neuropathy, stroke, and cardiac arrhythmia, among others. Despite all existing research results and reasonable speculations, knowledge about the role of purinergic system in individuals with DM and hypertension remains restricted. Purinergic signaling accounts for a complex network of receptors and extracellular enzymes responsible for the recognition and degradation of extracellular nucleotides and adenosine. The main components of this system that will be presented in this review are: P1 and P2 receptors and the enzymatic cascade composed by CD39 (NTPDase; with ATP and ADP as a substrate), CD73 (5′-nucleotidase; with AMP as a substrate), and adenosine deaminase (ADA; with adenosine as a substrate). The purinergic system has recently emerged as a central player in several physiopathological conditions, particularly those linked to inflammatory responses such as diabetes and hypertension. Therefore, the present review focuses on changes in both purinergic P1 and P2 receptor expression as well as the activities of CD39, CD73, and ADA in diabetes and hypertension conditions. It can be postulated that the manipulation of the purinergic axis at different levels can prevent or exacerbate the insurgency and evolution of diabetes and hypertension working as a compensatory mechanism.
Databáze: OpenAIRE